DCGO Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -9.79% compared to DocGo's net margin of 1.08%. DocGo's return on equity of -0.2% beat Astrana Health's return on equity of 7.09%.

DocGo has a consensus price target of $3.05, signalling upside risk potential of 99.34%. On the other hand Astrana Health has an analysts' consensus of $47.8889 which suggests that it could grow by 89.58%. Given that DocGo has higher upside potential than Astrana Health, analysts believe DocGo is more attractive than Astrana Health.

DocGo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.849, suggesting its less volatile than the S&P 500 by 15.081%.

DocGo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DocGo quarterly revenues are $96M, which are smaller than Astrana Health quarterly revenues of $620.4M. DocGo's net income of -$9.4M is lower than Astrana Health's net income of $6.7M. Notably, DocGo's price-to-earnings ratio is 8.24x while Astrana Health's PE ratio is 35.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo is 0.32x versus 0.54x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -9.79% compared to DocGo's net margin of 28%. DocGo's return on equity of -0.2% beat Biote's return on equity of --.

DocGo has a consensus price target of $3.05, signalling upside risk potential of 99.34%. On the other hand Biote has an analysts' consensus of $6.40 which suggests that it could grow by 67.05%. Given that DocGo has higher upside potential than Biote, analysts believe DocGo is more attractive than Biote.

DocGo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

DocGo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

DocGo quarterly revenues are $96M, which are larger than Biote quarterly revenues of $49M. DocGo's net income of -$9.4M is lower than Biote's net income of $13.7M. Notably, DocGo's price-to-earnings ratio is 8.24x while Biote's PE ratio is 6.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo is 0.32x versus 0.67x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -9.79% compared to DocGo's net margin of 3.55%. DocGo's return on equity of -0.2% beat Cryo-Cell International's return on equity of --.

DocGo has a consensus price target of $3.05, signalling upside risk potential of 99.34%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 63.78%. Given that DocGo has higher upside potential than Cryo-Cell International, analysts believe DocGo is more attractive than Cryo-Cell International.

DocGo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.015%.

DocGo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 12.52% to investors and pays a quarterly dividend of $0.15 per share. DocGo pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

DocGo quarterly revenues are $96M, which are larger than Cryo-Cell International quarterly revenues of $8M. DocGo's net income of -$9.4M is lower than Cryo-Cell International's net income of $282.9K. Notably, DocGo's price-to-earnings ratio is 8.24x while Cryo-Cell International's PE ratio is 519.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo is 0.32x versus 1.32x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -9.79% compared to DocGo's net margin of -5.49%. DocGo's return on equity of -0.2% beat P3 Health Partners's return on equity of -53.56%.

DocGo has a consensus price target of $3.05, signalling upside risk potential of 99.34%. On the other hand P3 Health Partners has an analysts' consensus of $14.00 which suggests that it could grow by 111.48%. Given that P3 Health Partners has higher upside potential than DocGo, analysts believe P3 Health Partners is more attractive than DocGo.

DocGo has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

DocGo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

DocGo quarterly revenues are $96M, which are smaller than P3 Health Partners quarterly revenues of $373.2M. DocGo's net income of -$9.4M is higher than P3 Health Partners's net income of -$20.5M. Notably, DocGo's price-to-earnings ratio is 8.24x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo is 0.32x versus 0.01x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.